Editas Medicine (EDIT) to Release Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Stock Up 4.7 %

Editas Medicine stock opened at $2.01 on Tuesday. Editas Medicine has a 52 week low of $1.12 and a 52 week high of $11.58. The business has a 50-day simple moving average of $1.38 and a 200 day simple moving average of $2.54. The stock has a market cap of $165.92 million, a price-to-earnings ratio of -0.79 and a beta of 1.94.

Analyst Ratings Changes

EDIT has been the subject of a number of research reports. Stifel Nicolaus cut Editas Medicine from a “buy” rating to a “hold” rating and cut their price objective for the stock from $11.00 to $3.00 in a report on Friday, December 13th. Barclays cut their price objective on Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Friday, December 13th. Royal Bank of Canada cut their price objective on Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a report on Friday, December 13th. Evercore ISI cut their price objective on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, December 16th. Finally, Raymond James cut Editas Medicine from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Editas Medicine currently has a consensus rating of “Hold” and a consensus price target of $7.00.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.